Abstract:
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
Abstract:
The present invention relates to compounds useful as inhibitors of P13K, particularly of P13K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
Abstract:
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
Abstract:
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
Abstract:
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
Abstract:
The present invention relates to inhibitors of protein kinases of formula I. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Abstract:
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
Abstract:
The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1 beta converting enzyme ("ICE") inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1- ("IL-1"), apoptosis-, interferon- gamma inducing factor- (IGIF), or interferon- gamma - ("IFN- gamma ") mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN- gamma production and methods for treating interleukin-1, apoptosis-, and interferon- gamma - mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.
Abstract:
La invención se refiere a compuestos de triazol de la fórmula I y I' o sus sales farmacéuticamente aceptables, útiles como moduladores de enfermedades desmielinizantes:La invención también proporciona composiciones farmacéuticamente aceptables que comprende los compuestos de la invención, métodos de uso de las composiciones y sus kits en el tratamiento de diversas enfermedades desmielinizantes y neurodegenerativas, incluyendo esclerosis múltiple.